Biotech aTyr Pharma announced that its Phase 3 trial of efzofitimod failed to meet the primary endpoint of reducing steroid use in pulmonary sarcoidosis patients. The drug showed a modest, statistically insignificant improvement in steroid tapering compared to placebo. The trial result led to an 80% plunge in aTyr’s stock price. While aTyr still investigates further development, the failure casts uncertainty over its future prospects.